PAION AG
PA8 | F
Overview
Corporate Details
- ISIN(s):
- DE000A3E5EG5
- LEI:
- 529900CGHB9UWY40BU45
- Country:
- Germany
- Address:
- Heussstraße 25, 52078 Aachen
- Website:
- https://www.paion.com/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
PAION AG is a publicly listed specialty pharmaceutical company with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic. PAION has started to launch remimazolam (Byfavo) in selected European markets. Remimazolam is partnered in multiple territories outside of Europe. Remimazolam is approved in the U.S., the EU/EEA/UK, China and South Korea for procedural sedation and in Japan and South Korea for general anesthesia. In addition, PAION markets two intensive care products in selected European countries: Angiotensin II (GIAPREZA), a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock, and eravacycline (XERAVA), a novel fluorocycline type of antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2023-09-29 00:00 |
Quarterly Report
Half-yearly financial report 2023
|
English | 699.3 KB | |
| 2023-05-31 00:00 |
Annual Report
Annual financial report 2022
|
English | 1.8 MB | |
| 2023-05-22 00:00 |
Quarterly Report
Q1 statement / Q1 financial report 2023
|
English | 200.9 KB | |
| 2023-05-17 00:00 |
Annual Report
|
English | 1.6 MB | |
| 2022-11-17 00:00 |
Quarterly Report
Q3 statement / Q3 financial report 2022
|
English | 110.5 KB | |
| 2022-09-05 00:00 |
Quarterly Report
Half-yearly financial report 2022
|
English | 518.2 KB | |
| 2022-05-18 00:00 |
Quarterly Report
Q1 statement / Q1 financial report 2022
|
English | 150.6 KB | |
| 2022-04-08 00:00 |
Annual Report
Annual financial report 2021
|
English | 1.7 MB | |
| 2021-11-12 00:00 |
Quarterly Report
Q3 statement / Q3 financial report 2021
|
English | 198.2 KB | |
| 2021-08-24 00:00 |
Quarterly Report
Half-yearly financial report 2021
|
English | 1.1 MB | |
| 2021-05-12 00:00 |
Quarterly Report
Q1 statement / Q1 financial report 2021
|
English | 136.2 KB | |
| 2021-04-16 00:00 |
Annual Report
Annual financial report 2020
|
English | 1.4 MB | |
| 2020-11-18 00:00 |
Quarterly Report
Q3 statement / Q3 financial report 2020
|
English | 118.2 KB | |
| 2020-08-13 00:00 |
Quarterly Report
Half-yearly financial report 2020
|
English | 398.5 KB | |
| 2020-05-13 00:00 |
Quarterly Report
Q1 statement / Q1 financial report 2020
|
English | 119.3 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-12-27 | Siebert, Gregor | Board | Buy | None | 24,110.26 EUR |
| 2022-12-22 | Dieckow, StB Simone | Close relation | Buy | None | 500,000.00 EUR |
| 2022-12-22 | Fuchs, Anna-Louisa | Close relation | Other | None | N/A |
| 2022-12-21 | Zeitfracht GmbH & Co. KGaA | Close relation | Buy | None | 3,607,500.00 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
AstraZeneca PLC | United Kingdom | AZN | |
|
Basilea Pharmaceutica AG | Switzerland | BSLN | |
|
Bayer AG | Germany | BAY | |
|
Biogened Spolka Akcyjna | Poland | BGD | |
|
Biotika A.S. | Slovakia | BSL | |
|
Bio Vitos Pharma AB | Sweden | BIOVIT | |
|
BOIRON | France | BOI | |
|
Bonyf N.V. | Belgium | MLBON | |
|
Bosnalijek d.d. Sarajevo | Bosnia and Herzegovina | BSNL | |
|
Calliditas Therapeutics | Sweden | CALTX |